Epidermolysis Bullosa

Mar 25, 2024

Gene Therapies for Epidermolysis Bullosa Treatment: The Next Frontier in Dermatology

Jan 02, 2024

Cytokinetics Announces Results From SEQUOIA-HCM Clinical Trial of Aficamten; FDA Approves Chiesi’s FILSUVEZ Topical Gel; Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform; AstraZeneca to Acquire Gracell; Zevra Therapeutics Announces Resubmission of Arimoclomol New Drug Application; Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362)

May 08, 2023

Watershed Moment for Cell Therapies and Complicated Journey of Gene Therapies in Japan

Mar 28, 2023

Novartis Announces the Positive Results of Phase III NATALEE Trial Evaluating Kisqali; FDA Approves Pharming’s Joenja for APDS; FDA Orphan Drug Designation to Cyclerion’s Zagociguat; Iovance Completes BLA Submission for Lifileucel in Advanced Melanoma; BPGbio Announces Partnership with debra of America

Nov 02, 2020

Pharma Players Line Up To Launch Novel Therapies Fueling Epidermolysis Bullosa Market Size

Newsletter/Whitepaper